BEAMBeam Therapeutics Inc
Slide 1 of 3
Company Overview
Name
Beam Therapeutics Inc
52W High
$35.25
52W Low
$13.53
Market Cap
$2.1B
Dividend Yield
0%
Price/earnings
-1.1
P/E
-1.1
Dividends
No dividend
Sentiment
Score
Very Bullish
82
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 2 of 3
Income Statement
Total Revenue
$9.7M
Operating Revenue
$9.7M
Total Gross Profit
$9.7M
Total Operating Income
$-126.8M
Net Income
$-112.7M
EV to EBITDA
$0.00
EV to Revenue
$18.94
Price to Book value
$2.20
Price to Earnings
$0.00
Additional Data
Selling, General & Admin Expense
$26.7M
Research & Development Expense
$109.8M
Total Operating Expenses
$-136.5M
Interest Expense
$10.9M
Other Income / (Expense), net
$3.2M
Total Other Income / (Expense), net
$14.1M
Slide 3 of 3
Earnings History
Estimated EPS
Reported EPS
N/A Slide 1 of 5
Company Overview
Name
Beam Therapeutics Inc
52W High
$35.25
52W Low
$13.53
Market Cap
$2.1B
Dividend Yield
0%
Price/earnings
-1.1
P/E
-1.1
Dividends
No dividend
Slide 2 of 5
Sentiment
Score
Very Bullish
82
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 3 of 5
Income Statement
Total Revenue
$9.7M
Operating Revenue
$9.7M
Total Gross Profit
$9.7M
Total Operating Income
$-126.8M
Net Income
$-112.7M
EV to EBITDA
$0.00
EV to Revenue
$18.94
Price to Book value
$2.20
Price to Earnings
$0.00
Slide 4 of 5
Additional Data
Selling, General & Admin Expense
$26.7M
Research & Development Expense
$109.8M
Total Operating Expenses
$-136.5M
Interest Expense
$10.9M
Other Income / (Expense), net
$3.2M
Total Other Income / (Expense), net
$14.1M
Slide 5 of 5
Earnings History
Estimated EPS
Reported EPS
N/AUpcoming Earnings
We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
John Evans
Location
Massachusetts, USA
Exchange
Nasdaq
Website
https://beamtx.com
Summary
Beam Therapeutics Inc.
Company Info
CEO
John Evans
Location
Massachusetts, USA
Exchange
Nasdaq
Website
https://beamtx.com
Summary
Beam Therapeutics Inc.
